Ftse Mib
34.346,93
-0,90%
DAX
18.563,79
-0,65%
S&P 500
5.306,04
0,02%
NASDAQ
0,00
0,00%
Bitcoin
67.845,85
-0,65%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Calliditas Therapeutics AB (CALT) Calliditas Therapeutics AB (CALT) Notizie

CALT

Calliditas Therapeutics AB (CALT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CALT
DataOraFonteTitoloSimboloCompagnia
28/05/202414:46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
28/05/202414:09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409:17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
23/05/202407:55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202408:45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202414:30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202413:36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202413:52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202408:16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
24/04/202419:35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202409:30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202413:13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202413:24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202414:38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202409:24PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
12/03/202402:28PR Newswire (US)Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®NASDAQ:CALTCalliditas Therapeutics AB
06/03/202408:38PR Newswire (US)Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®NASDAQ:CALTCalliditas Therapeutics AB
01/03/202413:43PR Newswire (US)Calliditas Therapeutics to Attend Investor Conferences in MarchNASDAQ:CALTCalliditas Therapeutics AB
21/02/202407:45PR Newswire (US)Calliditas Year-end report, January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
14/02/202407:11PR Newswire (US)Invitation to the presentation of Calliditas´ Year-end report January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
13/02/202417:28PR Newswire (US)Calliditas provides patent updateNASDAQ:CALTCalliditas Therapeutics AB
08/01/202408:33PR Newswire (US)Calliditas Therapeutics provides business update ahead of JP Morgan conferenceNASDAQ:CALTCalliditas Therapeutics AB
07/01/202417:21PR Newswire (US)Calliditas Therapeutics appoints Maria Törnsén as President North AmericaNASDAQ:CALTCalliditas Therapeutics AB
07/01/202417:07PR Newswire (US)Calliditas to present at JP Morgan Healthcare ConferenceNASDAQ:CALTCalliditas Therapeutics AB
27/12/202318:22PR Newswire (US)Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalNASDAQ:CALTCalliditas Therapeutics AB
21/12/202301:00Dow Jones NewsStocks to Watch: Micron, Warner Bros. Discovery, Paramount Global, Calliditas TherapeuticsNASDAQ:CALTCalliditas Therapeutics AB
20/12/202323:33Dow Jones NewsCalliditas Therapeutics Shares Rise 33% After FDA Approves TarpeyoNASDAQ:CALTCalliditas Therapeutics AB
20/12/202322:34PR Newswire (US)Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney functionNASDAQ:CALTCalliditas Therapeutics AB
11/12/202315:40PR Newswire (US)Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®NASDAQ:CALTCalliditas Therapeutics AB
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CALT

La tua Cronologia

BIT
UB78F3
Unicredit Bank
USOTC
SYFPV
Synchrony Financiall (PK)
BMF
VF2N24P001075
VF2N24P001075 - 07/2024
GEMN
FXSUSD
Frax Share
BITMOT
895694
Bs Green Tv Dc30 Amort C...
COIN
KINTTUSD
Kintsugi
COIN
CCV2UST
CryptoCart V2
DOWI
DJCIISIP
DJ Commodity Index Inver...
COIN
NEVAGBP
BIT
P1TKE2
BNP Paribas Issuance
NASDAQ
MSPD
NASDAQ
TCFC
Community Financial
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network